|
시장보고서
상품코드
2040796
에스트로겐 대체요법 시장 규모, 점유율 및 동향 분석 보고서 : 치료법별, 투여 경로별, 적응증별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)Estrogen Replacement Therapy Market Size, Share & Trends Analysis Report By Therapy Type (ET, EPT), By Route Of Administration (Oral, Transdermal), By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
에스트로겐 대체요법 시장 개요
세계의 에스트로겐 대체요법 시장 규모는 2025년에 117억 5,000만 달러로 추계되며, 2033년까지 183억 6,000만 달러에 달할 것으로 예측됩니다.
2026-2033년 CAGR 5.80%로 성장할 것으로 예상됩니다. 이 시장은 주로 전 세계 폐경기 및 폐경 후 여성 인구의 증가에 의해 주도되고 있습니다.
평균 수명의 연장으로 여성들이 갱년기 관련 증상을 경험하는 기간이 길어지면서 장기적인 호르몬 관리 솔루션에 대한 수요가 증가하고 있습니다. 또한 골다공증, 심혈관 질환 등 폐경과 관련된 건강 위험에 대한 인식이 높아지면서 에스트로겐 대체요법(ERT)의 조기 도입이 증가하고 있습니다. 삶의 질(QOL) 향상을 원하는 환자들의 성향이 강화되고 있는 것도 시장 확대를 더욱 부추기고 있습니다. 에스트로겐 대체요법은 갱년기 증상 관리와 전반적인 삶의 질 향상에 중요한 역할을 하고 있으며, 전 세계 여성들에게 널리 보급되고 있습니다. 안전성 프로파일을 개선하고 개별화된 투여 옵션을 제공하는 첨단 에스트로겐 대체요법 제제에 대한 수요가 증가하면서 혁신과 수용을 촉진하고 있습니다. 또한 환자의 복약 순응도와 편의성을 높이기 위해 경피 패치, 젤, 경구 요법 등 다양한 투여 형태에 대한 의식의 향상와 의사의 권고로 인해 다양한 투여 형태의 사용이 촉진되고 있습니다. 제약회사들은 생물학적 동등 호르몬, 저용량 요법, 환자 친화적인 투여 시스템에 중점을 두고 차세대 에스트로겐 대체요법의 연구개발에 적극적으로 투자하고 있습니다. 예를 들어 2024년 9월 화이자는 MHT에 대한 임상의의 지식을 향상시키기 위해 60만 달러 규모의 경쟁적 의학 교육 보조금 프로그램을 시작했습니다. 2024년 10월까지 신청을 받는 이 구상은 교육적 장벽을 없애고 에스트로겐 대체요법에 대한 근거에 기반한 접근성을 보장함으로써 시장 보급을 직접적으로 지원합니다.
또한 제약사들의 지속적인 제품 혁신과 전략적 노력도 시장에 긍정적인 영향을 미치고 있습니다. 안전성 프로파일을 개선하고 부작용을 줄인 새로운 제형은 호르몬 요법과 관련된 기존의 우려를 해결하고 있습니다. 또한 규제 당국의 승인 증가와 생체 동일성 호르몬에 대한 지속적인 연구로 인해 치료 옵션이 확대되고 있습니다. 각 업체들은 시장에서의 입지를 강화하기 위해 제휴, 제품 출시 및 사업 지역 확대에 힘쓰고 있습니다. 이러한 지속적인 혁신 파이프라인을 통해 전 세계에서 에스트로겐 대체요법의 보급이 더욱 가속화될 것으로 예상됩니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 개요
제3장 에스트로겐 대체요법 시장 : 변수, 동향, 범위
제4장 에스트로겐 대체요법 시장 : 치료법별 사업 분석
제5장 에스트로겐 대체요법 시장 : 투여 경로별 비즈니스 분석
제6장 에스트로겐 대체요법 시장 : 적응증별 비즈니스 분석
제7장 에스트로겐 대체요법 시장 : 유통 채널별 비즈니스 분석
제8장 에스트로겐 대체요법 시장 : 지역별 추정·동향 분석
제9장 경쟁 구도
KSA 26.06.02Estrogen Replacement Therapy Market Summary
The global estrogen replacement therapy market size was estimated at USD 11.75 billion in 2025 and is projected to reach USD 18.36 billion by 2033, growing at a CAGR of 5.80% from 2026 to 2033. The market is primarily driven by the rising global population of menopausal and postmenopausal women.
Increasing life expectancy has extended the duration women experience menopause-related symptoms, thereby boosting the demand for long-term hormone management solutions. In addition, greater awareness about menopause-associated health risks, such as osteoporosis and cardiovascular conditions, is encouraging early adoption of ERT. Growing patient inclination toward improving quality of life further supports market expansion. Estrogen replacement therapy continues to play a critical role in managing menopausal symptoms and improving overall quality of life, driving its widespread adoption among women globally. Rising demand for advanced estrogen replacement therapy formulations that offer improved safety profiles and personalized dosing options is boosting innovation and acceptance. Increasing awareness and physician recommendations are also encouraging the use of various delivery formats, including transdermal patches, gels, and oral therapies, to enhance patient adherence and convenience. Pharmaceutical companies are actively investing in R&D for next-generation estrogen replacement therapies, focusing on bioidentical hormones, low-dose regimens, and patient-friendly delivery systems. For instance, in September 2024, Pfizer launched a USD 600,000 competitive medical education grant program to improve clinician knowledge of MHT. This initiative, which accepted applications through October 2024, directly supports market adoption by addressing educational barriers and ensuring evidence-based accessibility for estrogen replacement therapies.
The market is also benefiting from continuous product innovation and strategic initiatives by pharmaceutical companies. New formulations with improved safety profiles and reduced side effects are addressing previous concerns associated with hormone therapy. Moreover, increasing regulatory approvals and ongoing research into bioidentical hormones are expanding treatment options. Companies are engaging in partnerships, product launches, and geographic expansions to strengthen their market presence. This ongoing innovation pipeline is expected to further accelerate the adoption of estrogen replacement therapy globally.
Global Estrogen Replacement Therapy Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global estrogen replacement therapy market report based on therapy type, route of administration, indication, distribution channel, and region:
- Therapy Type Outlook (Revenue, USD Billion, 2021 - 2033)
- Estrogen-only therapy (ET)
- Combined estrogen + progestin therapy (EPT)
- Bioidentical hormone therapy
- Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
- Oral
- Transdermal
- Vaginal
- Parenteral
- Indication Outlook (Revenue, USD Billion, 2021 - 2033)
- Menopause management
- Osteoporosis prevention/treatment
- Hypogonadism
- Others
- Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Therapy Type
- 1.2.2. Route of Administration
- 1.2.3. Indication
- 1.2.4. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Route of Administration & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Estrogen Replacement Therapy Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Estrogen Replacement Therapy Market: Therapy Type Business Analysis
- 4.1. Therapy Type Market Share, 2025 & 2033
- 4.2. Therapy Type Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Therapy Type, 2021 to 2033 (USD Billion)
- 4.4. Estrogen-Only Therapy (ET)
- 4.4.1. Estrogen-Only Therapy (ET) Market, 2021 - 2033 (USD Billion)
- 4.5. Combined Estrogen + Progestin Therapy (EPT)
- 4.5.1. Combined Estrogen + Progestin Therapy (EPT) Market, 2021 - 2033 (USD Billion)
- 4.6. Bioidentical Hormone Therapy
- 4.6.1. Bioidentical Hormone Therapy Market, 2021 - 2033 (USD Billion)
Chapter 5. Estrogen Replacement Therapy Market: Route of Administration Business Analysis
- 5.1. Route of Administration Market Share, 2025 & 2033
- 5.2. Route of Administration Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
- 5.4. Oral
- 5.4.1. Oral Market, 2021 - 2033 (USD Billion)
- 5.5. Transdermal
- 5.5.1. Transdermal Market, 2021 - 2033 (USD Billion)
- 5.6. Vaginal
- 5.6.1. Vaginal Market, 2021 - 2033 (USD Billion)
- 5.7. Parenteral
- 5.7.1. Parenteral Market, 2021 - 2033 (USD Billion)
Chapter 6. Estrogen Replacement Therapy Market: Indication Business Analysis
- 6.1. Indication Market Share, 2025 & 2033
- 6.2. Indication Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
- 6.4. Menopause Management
- 6.4.1. Menopause Management Market, 2021 - 2033 (USD Billion)
- 6.5. Osteoporosis prevention/treatment
- 6.5.1. Osteoporosis prevention/treatment Market, 2021 - 2033 (USD Billion)
- 6.6. Hypogonadism
- 6.6.1. Hypogonadism Market, 2021 - 2033 (USD Billion)
- 6.7. Others
- 6.7.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 7. Estrogen Replacement Therapy Market: Distribution Channel Business Analysis
- 7.1. Distribution Channel Market Share, 2025 & 2033
- 7.2. Distribution Channel Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
- 7.4. Hospital Pharmacies
- 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
- 7.5. Retail Pharmacies
- 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
- 7.6. Online Pharmacies
- 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Billion)
Chapter 8. Estrogen Replacement Therapy Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2025 & 2033
- 8.2. Regional Market Dashboard
- 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
- 8.4. North America
- 8.4.1. North America Estrogen Replacement Therapy Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
- 8.4.2. U.S.
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Target Disease Prevalence
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. Reimbursement Framework
- 8.4.2.5. U.S. Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.4.3. Canada
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Target Disease Prevalence
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. Reimbursement Framework
- 8.4.3.5. Canada Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.4.4. Mexico
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Target Disease Prevalence
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. Reimbursement Framework
- 8.4.4.5. Mexico Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5. Europe
- 8.5.1. Europe Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.2. UK
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Target Disease Prevalence
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Reimbursement Framework
- 8.5.2.5. UK Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.3. Germany
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Target Disease Prevalence
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Reimbursement Framework
- 8.5.3.5. Germany Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.4. France
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Target Disease Prevalence
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. Reimbursement Framework
- 8.5.4.5. France Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.5. Italy
- 8.5.5.1. Key Country Dynamics
- 8.5.5.2. Target Disease Prevalence
- 8.5.5.3. Regulatory Framework
- 8.5.5.4. Reimbursement Framework
- 8.5.5.5. Italy Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.6. Spain
- 8.5.6.1. Key Country Dynamics
- 8.5.6.2. Target Disease Prevalence
- 8.5.6.3. Regulatory Framework
- 8.5.6.4. Reimbursement Framework
- 8.5.6.5. Spain Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.7. Denmark
- 8.5.7.1. Key Country Dynamics
- 8.5.7.2. Target Disease Prevalence
- 8.5.7.3. Regulatory Framework
- 8.5.7.4. Reimbursement Framework
- 8.5.7.5. Denmark Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.8. Sweden
- 8.5.8.1. Key Country Dynamics
- 8.5.8.2. Target Disease Prevalence
- 8.5.8.3. Regulatory Framework
- 8.5.8.4. Reimbursement Framework
- 8.5.8.5. Sweden Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.9. Norway
- 8.5.9.1. Key Country Dynamics
- 8.5.9.2. Target Disease Prevalence
- 8.5.9.3. Regulatory Framework
- 8.5.9.4. Reimbursement Framework
- 8.5.9.5. Norway Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6. Asia Pacific
- 8.6.1. Asia Pacific Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.2. Japan
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Target Disease Prevalence
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Reimbursement Framework
- 8.6.2.5. Japan Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.3. China
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Target Disease Prevalence
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Reimbursement Framework
- 8.6.3.5. China Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.4. India
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Target Disease Prevalence
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. Reimbursement Framework
- 8.6.4.5. India Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.5. Australia
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Target Disease Prevalence
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Reimbursement Framework
- 8.6.5.5. Australia Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.6. South Korea
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Target Disease Prevalence
- 8.6.6.3. Regulatory Framework
- 8.6.6.4. Reimbursement Framework
- 8.6.6.5. South Korea Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.7. Thailand
- 8.6.7.1. Key Country Dynamics
- 8.6.7.2. Target Disease Prevalence
- 8.6.7.3. Regulatory Framework
- 8.6.7.4. Reimbursement Framework
- 8.6.7.5. Thailand Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.7. Latin America
- 8.7.1. Latin America Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.7.2. Brazil
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Target Disease Prevalence
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. Reimbursement Framework
- 8.7.2.5. Brazil Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.7.3. Argentina
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Target Disease Prevalence
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. Reimbursement Framework
- 8.7.3.5. Argentina Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8. Middle East and Africa
- 8.8.1. Middle East and Africa Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.2. South Africa
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Target Disease Prevalence
- 8.8.2.3. Regulatory Framework
- 8.8.2.4. Reimbursement Framework
- 8.8.2.5. South Africa Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Target Disease Prevalence
- 8.8.3.3. Regulatory Framework
- 8.8.3.4. Reimbursement Framework
- 8.8.3.5. Saudi Arabia Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.4. UAE
- 8.8.4.1. Key Country Dynamics
- 8.8.4.2. Target Disease Prevalence
- 8.8.4.3. Regulatory Framework
- 8.8.4.4. Reimbursement Framework
- 8.8.4.5. UAE Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.5. Kuwait
- 8.8.5.1. Key Country Dynamics
- 8.8.5.2. Target Disease Prevalence
- 8.8.5.3. Regulatory Framework
- 8.8.5.4. Reimbursement Framework
- 8.8.5.5. Kuwait Estrogen Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 9. Competitive Landscape
- 9.1. Participant Overview
- 9.2. Company Market Position Analysis
- 9.3. Company Categorization
- 9.4. Strategy Mapping
- 9.5. Company Profiles/Listing
- 9.5.1. Pfizer Inc.
- 9.5.1.1. Overview
- 9.5.1.2. Financial Performance
- 9.5.1.3. Therapy Type Benchmarking
- 9.5.1.4. Strategic Initiatives
- 9.5.2. AbbVie Inc.
- 9.5.2.1. Overview
- 9.5.2.2. Financial Performance
- 9.5.2.3. Therapy Type Benchmarking
- 9.5.2.4. Strategic Initiatives
- 9.5.3. Bayer AG
- 9.5.3.1. Overview
- 9.5.3.2. Financial Performance
- 9.5.3.3. Therapy Type Benchmarking
- 9.5.3.4. Strategic Initiatives
- 9.5.4. Eli Lilly and Company.
- 9.5.4.1. Overview
- 9.5.4.2. Financial Performance
- 9.5.4.3. Therapy Type Benchmarking
- 9.5.4.4. Strategic Initiatives
- 9.5.5. Novo Nordisk A/S
- 9.5.5.1. Overview
- 9.5.5.2. Financial Performance
- 9.5.5.3. Therapy Type Benchmarking
- 9.5.5.4. Strategic Initiatives
- 9.5.6. Novartis AG
- 9.5.6.1. Overview
- 9.5.6.2. Financial Performance
- 9.5.6.3. Therapy Type Benchmarking
- 9.5.6.4. Strategic Initiatives
- 9.5.7. Merck & Co., Inc.
- 9.5.7.1. Overview
- 9.5.7.2. Financial Performance
- 9.5.7.3. Therapy Type Benchmarking
- 9.5.7.4. Strategic Initiatives
- 9.5.8. F. Hoffmann-La Roche Ltd.
- 9.5.8.1. Overview
- 9.5.8.2. Financial Performance
- 9.5.8.3. Therapy Type Benchmarking
- 9.5.8.4. Strategic Initiatives
- 9.5.9. Viatris Inc.
- 9.5.9.1. Overview
- 9.5.9.2. Financial Performance
- 9.5.9.3. Therapy Type Benchmarking
- 9.5.9.4. Strategic Initiatives
- 9.5.10. Teva Pharmaceutical Industries Ltd.
- 9.5.10.1. Overview
- 9.5.10.2. Financial Performance
- 9.5.10.3. Therapy Type Benchmarking
- 9.5.10.4. Strategic Initiatives
- 9.5.1. Pfizer Inc.
